BioPhorum Unites 20 Organizations to Modernize Small Molecule Production

BioPhorum, a global forum for biopharmaceutical industry collaboration, has formed a new working group aimed at accelerating innovation across small molecule manufacturing.1 The Synthetic Molecule Process Innovation Phorum brings together 20 organizations spanning global pharmaceutical companies, specialist CDMOs, technology providers, and regulatory bodies, with the goal of aligning the broader ecosystem around faster, more coordinated adoption of new manufacturing approaches.

Participants include major pharmaceutical manufacturers alongside regulatory and standards bodies, such as the UK's Medicines and Healthcare products Regulatory Agency, the British Pharmacopoeia, and the US Pharmacopeia.1 Their involvement signals an intent to make the group a direct channel between industry practice and regulatory expectations, rather than a forum limited to internal industry discussion.

Why Is Small Molecule Manufacturing Under Pressure?

The initiative responds to a shift already underway in drug development pipelines.1 Small molecule therapies, once associated largely with niche or high-potency compounds, are increasingly central to high-volume treatments in oncology, neurology, obesity, and immunology. That shift is placing new demands on manufacturing infrastructure, which must scale efficiently while maintaining supply chain resilience. “As pipelines fill with complex small molecules, from next‑generation obesity treatments to breakthrough therapies in oncology and immunology, the question is no longer whether science can deliver, but whether manufacturing can keep up,” stated Andrea Johnston, senior director, BioPhorum, in a press release.1 “By bringing global pharma and specialist CDMOs around one table, the BioPhorum Synthetic Molecule Process Innovation is designed to turn market momentum into robust, efficient, and sustainable ways of making these products at scale.”

This framing matters because it reflects a broader industry pattern: therapeutic innovation is outrunning the operational systems meant to support it.1 Facilities built around older production assumptions may struggle to accommodate the complexity and scale of newer synthetic molecule pipelines without coordinated updates to process design, regulatory guidance, and data infrastructure.

What Will the Group Work On?

Following a two-day planning session in Cork, Ireland, the collaboration identified four initial focus areas.1 The first addresses peptide manufacturing, specifically capacity constraints and raw material availability, which have become recurring bottlenecks as peptide-based therapies expand. The second targets regulatory alignment, including global acceptance of solvent reuse practices and clearer chemistry, manufacturing, and controls guidance for synthetic peptide production under biologics license applications. The third focuses on model-based predictive control, aiming to develop frameworks for robust, end-to-end control strategies across manufacturing processes. The fourth centers on knowledge lifecycle management, an effort to standardize how data are shared and interpreted across a product's development and manufacturing lifecycle.

Each of these areas touches a persistent operational challenge in the sector: fragmented regulatory expectations across regions, inconsistent data practices between organizations, and supply constraints that can delay production timelines even when clinical development proceeds smoothly.1 A coordinated, cross-industry approach to these issues could reduce duplicated effort among individual companies working through similar problems independently.

The launch also reflects a wider consolidation trend among industry organizations that support manufacturing best practices, as groups expand their scope to address adjacent operational challenges rather than operating within narrower technical silos.1

The formation of this group is worth monitoring less for what it announces today than for what it may produce over time: potential shifts in regulatory guidance, emerging standards for predictive control systems, and clearer expectations around peptide manufacturing that could influence facility planning and compliance strategy in the coming years.1

What Does Market Growth Show About the Urgency Behind This Collaboration?

Recent figures reinforce the timing of BioPhorum's initiative.2 The global small molecule API contract development and manufacturing market was valued at $46.6 billion in 2025 and is projected to grow to $80.7 billion by 2033, expanding at a compound annual rate of 7.3%. Analysts attribute this growth partly to rising demand for complex APIs, supply chain resilience initiatives amid shifting geopolitics, and increasing digitalization and regulatory evolution. Phorum's four work streams aim to address these same pressures collectively rather than company by company.

References

1. BioPhorum. BioPhorum unites regulators, big pharma and CDMOs to accelerate synthetic molecule innovation. Press release. July 1, 2026.
2. Grand View Research. Small molecule CDMO market size | industry report, 2026. July 1, 2026. https://www.grandviewresearch.com/industry-analysis/small-molecule-cdmo-market-report.